Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis and Astellas Pharma have agreed to restructure their joint venture activities for Fujisawa Sanofi-Aventis in Japan.
Subscribe to our email newsletter
This operation, that will simplify the operational management, will be made in several steps and the process is expected to be completed substantially on December 31, 2007.
Established in 1982, Fujisawa Sanofi-Aventis (FSA) is a joint venture company 51% owned by Sanofi-Aventis and 49% by Astellas. FSA owns the rights to manufacture and sell certain products originating from Sanofi-Aventis such as Myslee (zolpidem), Dogmatyl (sulpiride), Primperan (metoclopramide) and Gramalil (tiapride).
In the restructuring, Sanofi-Aventis KK, the Japanese subsidiary of Sanofi-Aventis, shall obtain certain rights to Myslee. Myslee, used for the treatment of insomnia, will continue to be co-promoted by Sanofi-Aventis KK and Astellas and distributed by Astellas. The other products, namely Primperan, Dogmatyl and Gramalil will solely be marketed and distributed by Astellas.